PERRONE, MARIA GRAZIA
 Distribuzione geografica
Continente #
NA - Nord America 7.348
AS - Asia 3.307
EU - Europa 2.395
SA - Sud America 835
AF - Africa 108
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.016
Nazione #
US - Stati Uniti d'America 7.207
SG - Singapore 1.433
CN - Cina 809
BR - Brasile 714
IT - Italia 616
HK - Hong Kong 454
SE - Svezia 405
RU - Federazione Russa 386
DE - Germania 243
VN - Vietnam 184
GB - Regno Unito 160
UA - Ucraina 140
FI - Finlandia 116
ID - Indonesia 108
CA - Canada 82
IN - India 72
FR - Francia 67
JP - Giappone 56
AR - Argentina 50
MX - Messico 42
BE - Belgio 41
CI - Costa d'Avorio 41
BD - Bangladesh 36
NL - Olanda 35
PL - Polonia 34
ES - Italia 27
TR - Turchia 27
AT - Austria 25
IE - Irlanda 22
IQ - Iraq 21
ZA - Sudafrica 21
AU - Australia 19
CZ - Repubblica Ceca 19
CH - Svizzera 17
IR - Iran 17
EC - Ecuador 16
VE - Venezuela 14
CL - Cile 13
LT - Lituania 13
UZ - Uzbekistan 13
EG - Egitto 11
KR - Corea 9
MA - Marocco 9
PY - Paraguay 9
TW - Taiwan 9
CO - Colombia 8
KE - Kenya 7
PK - Pakistan 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
IL - Israele 6
PE - Perù 6
AZ - Azerbaigian 5
HU - Ungheria 5
RO - Romania 5
TN - Tunisia 5
UY - Uruguay 5
BG - Bulgaria 4
GT - Guatemala 4
TT - Trinidad e Tobago 4
CR - Costa Rica 3
DZ - Algeria 3
GE - Georgia 3
JM - Giamaica 3
KZ - Kazakistan 3
LB - Libano 3
NP - Nepal 3
PS - Palestinian Territory 3
TZ - Tanzania 3
DK - Danimarca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GR - Grecia 2
KG - Kirghizistan 2
MK - Macedonia 2
MY - Malesia 2
NO - Norvegia 2
OM - Oman 2
PH - Filippine 2
PT - Portogallo 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
EE - Estonia 1
EU - Europa 1
GI - Gibilterra 1
JO - Giordania 1
ML - Mali 1
MM - Myanmar 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
ZW - Zimbabwe 1
Totale 14.016
Città #
Fairfield 824
Ashburn 793
Singapore 718
Chandler 592
Woodbridge 543
Hong Kong 452
Houston 430
Seattle 331
Nyköping 324
Jacksonville 318
Cambridge 311
Ann Arbor 295
Beijing 272
Wilmington 250
Bari 205
Dallas 202
New York 126
Los Angeles 116
Roxbury 108
Lawrence 106
Nanjing 95
Sannicandro di Bari 82
Ho Chi Minh City 65
São Paulo 65
Boardman 64
Des Moines 61
Brooklyn 60
Munich 58
Princeton 57
Dearborn 51
Inglewood 43
Jakarta 43
Santa Clara 43
Abidjan 41
Tokyo 41
Brussels 39
Buffalo 37
Milan 37
San Diego 37
Chicago 34
Hanoi 33
Moscow 32
London 31
Nanchang 30
Montreal 29
Warsaw 29
Council Bluffs 28
Frankfurt am Main 28
San Francisco 28
Jiaxing 27
Denver 26
Nuremberg 25
Hebei 24
Shenyang 24
Changsha 23
Florence 22
Toronto 22
Dublin 20
Rio de Janeiro 20
Orem 19
Stockholm 19
Belo Horizonte 18
Helsinki 18
Shanghai 18
The Dalles 18
Brno 17
Johannesburg 17
Columbus 16
Phoenix 16
Rome 16
Atlanta 15
Chennai 15
Manchester 15
Mexico City 15
Poplar 15
Amsterdam 14
Falkenstein 14
Bitonto 13
Boston 13
San Jose 13
Tashkent 13
Turku 13
Paris 12
Wuhan 12
Brasília 11
Catania 10
Guangzhou 10
Haiphong 10
Vienna 10
Washington 10
Ardabil 9
Augusta 9
Falls Church 9
Hefei 9
Istanbul 9
New Delhi 9
Norwalk 9
Porto Alegre 9
Pune 9
Redwood City 9
Totale 9.405
Nome #
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability 210
Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R) 186
4-Nitro-2,1,3-benzoxadiazole derivatives as potential fluorescent sigma receptor probes 179
4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators 175
COX-1 Inhibitors: Beyond Structure Toward Therapy 164
Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier 163
Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6) 160
Harmaline-based scaffold as Human Caseinolytic Protease P (hClpP) inducers for Diffuse Intrinsic Pontine Glioma (DIPG) treatment 158
Isoxazole-Based-Scaffold Inhibitors Targeting Cyclooxygenases (COXs) 157
PET radiotracer [18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: Preliminary investigation 154
Zoledronic acid modulation of TRPV1 channel currents in osteoblast cell line and native rat and mouse bone marrow-derived osteoblasts: Cell proliferation and mineralization effect 152
A Benzopyrane derivative as P-glycoprotein stimulator: a potential agent to decrease beta-amyloid accumulation in Alzheimer’s disease 151
Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators 149
Screening yeasts for the stereoselective reduction of oxoester clofibrate analogues 148
General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model 147
Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives 147
Design, Biological Evaluation and Molecular Modelling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-glycoprotein Ligand Overcoming Multi-Drug Resistance in Cancer Stem Cells. 146
Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection 140
Functionalized Coumarine Fragment to Obtain Fluorescent and Selective P-Glycoprotein Ligands 139
Baker's yeast-mediated reduction of ethyl 2-(4-chlorophenoxy)-3-oxoalkanoates intermediates for potential PPARa ligands 138
Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers 137
Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors 136
Synthesis, Pharmacological Characterization, and Docking Analysis of a Novel Family of Diarylisoxazoles as Highly Selective Cyclooxygenase‑1 (COX-1) Inhibitors 135
Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity 135
Selective cyclooxygenase-1 inhibition by P6 and gastrotoxicity: Preliminary investigation 134
Current and emerging applications of fluorine in medicinal chemistry 134
Update on SAR studies toward new COX-1 selective inhibitors 133
New tetrahydroisoquinoline-based P-glycoprotein modulators: Decoration of the biphenyl core gives selective ligands 133
In vitro evaluation of glycol chitosan based formulations as oral delivery systems for efflux pump inhibition 132
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells 131
Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4′-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein 131
Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Use-Dependent Inhibitors of Voltage-Gated Sodium Channels 131
Highly Selective Cyclooxygenase-1 Inhibitors P6 and Mofezolac Counteract Inflammatory State both In Vitro and In Vivo Models of Neuroinflammation 130
Beta 3-Adrenoceptor Agonists and (Antagonists as) Inverse Agonists: History, Perspective, Constitutive Activity, and Stereospecific Binding 129
Intelligent microarray data analysis through non-negative matrix factorization to study human multiple myeloma cell lines 129
A chemoenzymatic scalable route to optically active (R)-1-(pyridin-3-yl)-2-aminoethanol, valuable moiety of beta3-adrenergic receptor agonists 126
Synthesis, antiarrhythmic activity, and toxicological evaluation of mexiletine analogues 126
Stereoselective Modulation of P-Glycoprotein by Chiral Small Molecules 124
Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters 122
An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid 120
Beta 3-adrenoceptor ligand development history through patent review 117
Activity-lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragments 116
Lipase-mediated kinetic resolution of rigid clofibrate analogues, with lipid-modifying activity 112
Synthesis and Biological Evaluation of New Clofibrate Analogues as Potential PPARa Agonists 111
Synthesis and biological evaluation of 3-alkyloxazolidin-2-ones as reversible MAO inhibitors 110
6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers 110
Novel pyrazoles and their radiolabeled derivatives useful as COX-1 selective inhibitors 108
A Combined HPLC and LC-MS Approach for Evaluating Drug Stability in Elastomeric Devices: A Challenge for the Sustainability in Pharmacoeconomics 108
Structure-Activity Relationship Studies on 6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Multidrug Resistance Reversers. 108
Kluyveromyces marxianus CBS 6556 growing cells as a new biocatalyst in the asymmetric reduction of substituted acetophenones 107
Exploring prospects of β3-adrenoceptor agonists and inverse agonists for colon motility control 106
[18F]-P6 AS A CYCLOOXYGENASE-1 TARGETED IMAGING AGENT 105
Modulation and absorption of xenobiotics: the synergistic role of CYP450 and P-gp activities in cancer and neurodegenerative disorders 104
Selective COX-1 inhibition: a therapeutic target to be reconsidered 103
The tertiary amine nitrogen atom of piperazine sulfonamides as a novel determinant of potent and selective beta3-adrenoceptor agonists 102
A Potent and Selective P-gp Modulator for Altering Multidrug Resistance Due to Pump Overexpression 102
Bioethanol from biomass model fermentation by Kluyvromyces marxianus CBS6556 100
Vascular Toxicity Risk Assessment of MC18 and MC70, Novel Potential Diagnostic Tools for In Vivo PET Studies 100
Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders 100
A further pocket or conformational plasticity by mapping COX-1 catalytic site through modified-mofezolac structure-inhibitory activity relationships and their antiplatelet behavior 98
In-vivo administration of CLC-K kidney chloride channels inhibitors increases water diuresis in rats: A new drug target for hypertension? 97
Selective κ Opioid Antagonists nor-BNI, GNTI and JDTic Have Low Affinities for Non-Opioid Receptors and Transporters 95
CLC-K kidney chloride channels as drug target for hypertension: effects of acute in vivo administration to rats of newly synthesized inhibitors 94
BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY 92
Diastereo- and enantio-selective bioreduction of ethyl 2-(4-chlorophenoxy)-3-oxobutanoate clofibrate analogues by Kluyveromyces marxianus and other whole cell biocatalysts 91
NOVEL BISPHOSPHONATES, WITH ANTIRESORPTIVE EFFECT IN BONE MINERALIZATION AND OSTEOCLASTOGENESIS, AS MOIETIES OF RA 223-BASED RADIOTRACERS 91
Myogenic effect of SP-1f and SP-1h two novel 3-adrenoceptor (3-AR) agonists in human colonic circular smooth muscle 90
Acridone derivatives and small molecules as P-gp inhibitors 89
MODULATORS OF HUMAN MITOCHONDRIAL PROTEASE ClpP ACTIVITY FOR PEDIATRIC DIFFUSE PONTINE GLIOMA TREATMENT 88
Zoledronic acid as a novel dual blocker of KIR6.1/2-SUR2 subunits of ATP-sensitive K+ channels: Role in the adverse drug reactions 88
Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease 87
Diffuse Intrinsic Pontine Glioma (DIPG): breakthrough and clinical perspective 86
Cyclooxygenase-1 Inhibition: A Promising Theragnostic Approach for Ovarian Cancer 85
Highly selective COX-1 inhibitors as novel cardioprotective anti-thrombotic agents 85
Ligandi del recettore beta-3 adrenergico e loro uso in terapia 84
Comparative Structural Analysis of hCOX‑1 and oCOX‑1 Isoenzymes 83
MC225, a Novel Probe for P-glycoprotein PET imaging at the Blood-Brain Barrier: in vitro cardivascular safety evaluation 83
Substrates, inhibitors and activators of P-glycoprotein: candidates for radiolabeling and imaging perspectives 81
Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles 81
Bisphosphonates Targeting Ion Channels and Musculoskeletal Effects 79
Lipid-modifying agents by yeasts- and a novel ADH-mediated reduction of 3-oxoesters 78
Yeast and a novel ADH-mediated biosynthesis of new clofibrate analogues 77
Reaction of caesium 4-chlorophenate and chlorohydrins from threonines: synthesis of clofibrate analogues 77
Lipid-modifying agents by yeasts- and a novel ADH-mediated reduction of 3-oxoesters 76
Up-regulation of b3-adrenergic receptor mRNA in human colon cancer: a preliminary study 76
Translational Theragnosis of Ovarian Cancer: where do we stand? 75
Patient Bone Marrow Aspiration to Explore the Cyclooxygenases (COXs) Involvement in Multiple Myeloma 74
Bioassisted synthesis of 3-hydroxyacids resembling antilipidemic clofibric acid molecular structure 74
SAR study on Arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity 74
Three-dimensional structure of human cyclooxygenase (hCOX)-1 74
CYP3A4/P-gp sinergistic activity to modulate the absorption and delivery of xenobiotics 73
A Benzopyrane Derivative as a P-Glycoprotein Stimulator: A Potential Agent to Decrease β-Amyloid Accumulation in Alzheimer's Disease 72
Isoxazole and pyrazole core in COX-1 inhibitors 72
The concomitant effect of anti-MM drugs in combination with COX inhibitors 72
Mucoadhesive Properties and Interaction with P-glycoprotein (P-gp) of Thiolated-Chitosans and -Glycol Chitosans and Corresponding Parent Polymers: A Comparative Study 70
One molecule two goals: A selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells 70
β 3 -Adrenoceptor agonists and (Antagonists as) inverse agonists. History, perspective, constitutive activity, and stereospecific binding 69
null 69
Why PB28 Could Be a Covid 2019 Game Changer? 69
Ovine COX-1 Isoenzyme Bio-production 69
Totale 11.107
Categoria #
all - tutte 61.957
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.957


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021687 0 0 0 0 0 40 80 88 120 183 113 63
2021/2022933 77 113 23 18 41 70 49 50 67 77 129 219
2022/20231.543 200 183 136 121 181 206 15 182 232 21 41 25
2023/2024764 37 93 47 66 55 109 43 22 122 47 22 101
2024/20252.947 121 34 208 92 124 221 402 275 155 159 384 772
2025/20263.699 840 329 559 767 885 319 0 0 0 0 0 0
Totale 14.608